Profile data is unavailable for this security.
About the company
Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.
- Revenue in USD (TTM)1.00m
- Net income in USD-54.90m
- Incorporated2016
- Employees44.00
- LocationShattuck Labs Inc500 W. 5Th Street, Suite 100AUSTIN 78701United StatesUSA
- Phone+1 (512) 900-4690
- Websitehttps://www.shattucklabs.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Heron Therapeutics Inc | 154.90m | -20.20m | 226.24m | 128.00 | -- | 17.01 | -- | 1.46 | -0.1205 | -0.1205 | 0.8733 | 0.0761 | 0.6335 | 0.5668 | 1.84 | 1,210,188.00 | -8.26 | -41.54 | -13.40 | -61.25 | 73.31 | 60.34 | -13.04 | -88.20 | 1.51 | -0.2662 | 0.9075 | -- | 7.36 | 11.81 | -48.71 | -- | -45.86 | -- |
| CAMP4 Therapeutics Corp | 3.80m | -53.40m | 229.05m | 55.00 | -- | 3.53 | -- | 60.24 | -2.48 | -2.48 | 0.1746 | 1.25 | 0.0706 | -- | 1.81 | 69,127.27 | -99.11 | -- | -121.32 | -- | -- | -- | -1,404.47 | -- | -- | -- | 0.0013 | -- | 86.29 | -- | -5.07 | -- | -- | -- |
| Voyager Therapeutics Inc | 31.32m | -126.78m | 230.74m | 172.00 | -- | 1.05 | -- | 7.37 | -2.17 | -2.17 | 0.5358 | 3.96 | 0.0877 | -- | 2.64 | 182,069.80 | -35.50 | -1.01 | -39.95 | -1.27 | -- | -- | -404.85 | -2.34 | -- | -- | 0.00 | -- | -68.00 | -5.18 | -149.12 | -- | -14.53 | -- |
| Inhibikase Therapeutics Inc | 0.00 | -47.66m | 233.34m | 15.00 | -- | 1.98 | -- | -- | -1.15 | -1.15 | 0.00 | 0.9745 | 0.00 | -- | -- | 0.00 | -113.51 | -56.32 | -131.71 | -65.21 | -- | -- | -- | -1,965.97 | -- | -- | 0.00 | -- | -100.00 | -- | -44.62 | -- | -- | -- |
| Arcturus Therapeutics Holdings Inc | 97.60m | -66.71m | 237.24m | 174.00 | -- | 1.01 | -- | 2.43 | -2.46 | -2.46 | 3.60 | 8.25 | 0.2989 | -- | 5.12 | 560,919.60 | -20.43 | -19.22 | -24.18 | -24.16 | -- | -- | -68.35 | -68.95 | -- | -- | 0.00 | -- | -8.69 | 48.93 | -172.30 | -- | -4.55 | -- |
| Nuvectis Pharma Inc | 0.00 | -28.87m | 239.49m | 13.00 | -- | 12.61 | -- | -- | -1.31 | -1.31 | 0.00 | 0.7171 | 0.00 | -- | -- | 0.00 | -105.10 | -123.50 | -188.03 | -201.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -51.95 | -- | -- | -- |
| Angion Biomedica Corp | 0.00 | -45.86m | 242.05m | 32.00 | -- | 62.59 | -- | -- | -3.15 | -3.15 | 0.00 | 0.2211 | 0.00 | -- | -- | 0.00 | -137.56 | -106.87 | -179.35 | -289.86 | -- | -- | -- | -778.01 | -- | -302.49 | 0.7181 | -- | -- | -- | -47.46 | -- | -18.50 | -- |
| Alector Inc | 21.05m | -142.93m | 243.90m | 103.00 | -- | 7.96 | -- | 11.59 | -1.39 | -1.39 | 0.2043 | 0.2777 | 0.0553 | -- | -- | 204,320.40 | -37.54 | -18.23 | -50.42 | -22.68 | -- | -- | -679.16 | -100.47 | -- | -- | 0.2402 | -- | -79.07 | -0.0503 | -20.06 | -- | -61.79 | -- |
| CapForce Inc | 9.00m | 6.70m | 245.05m | 1.00 | 36.44 | 23.80 | 35.56 | 27.23 | 0.6585 | 0.6585 | 0.8894 | 1.01 | 0.994 | -- | 4.42 | 9,000,000.00 | 75.58 | -74.71 | 81.77 | -111.02 | 100.00 | 30.79 | 76.04 | -602.64 | -- | -- | 0.00 | -- | 52.01 | 8.23 | 134.76 | -- | -- | -- |
| Surrozen Inc | 3.60m | -86.91m | 245.14m | 40.00 | -- | -- | -- | 68.02 | -19.76 | -19.76 | 0.6008 | -2.74 | 0.0507 | -- | 0.4882 | 90,100.00 | -122.36 | -60.48 | -134.33 | -68.26 | -- | -- | -2,411.38 | -993.19 | -- | -- | -- | -- | -- | -- | -47.68 | -- | -55.92 | -- |
| Achieve Life Sciences Inc | 0.00 | -52.35m | 245.94m | 25.00 | -- | 7.26 | -- | -- | -1.38 | -1.38 | 0.00 | 0.6365 | 0.00 | -- | -- | 0.00 | -104.74 | -95.73 | -125.36 | -142.31 | -- | -- | -- | -- | -- | -- | 0.2271 | -- | -- | -- | -33.58 | -- | -- | -- |
| Shattuck Labs Inc | 1.00m | -54.90m | 253.12m | 44.00 | -- | 2.71 | -- | 253.12 | -1.02 | -1.02 | 0.0178 | 1.48 | 0.0094 | -- | -- | 22,727.27 | -51.77 | -32.04 | -56.50 | -35.04 | -- | -- | -5,489.50 | -721.60 | -- | -- | 0.00 | -- | 245.26 | -10.36 | 13.62 | -- | -33.97 | -- |
| OmniAB Inc | 21.09m | -63.67m | 253.36m | 114.00 | -- | 0.9132 | -- | 12.01 | -0.5906 | -0.5906 | 0.1956 | 1.93 | 0.0658 | -- | 6.40 | 185,035.10 | -19.86 | -- | -20.75 | -- | 27.71 | -- | -301.83 | -101.09 | 4.96 | -- | 0.00 | -- | -22.75 | 7.58 | -22.55 | -- | 49.04 | -- |
| Sol Gel Technologies Ltd | 18.97m | -8.99m | 255.12m | 34.00 | -- | 9.80 | -- | 13.45 | -3.23 | -3.23 | 6.81 | 9.34 | 0.4891 | -- | 2.25 | 557,941.20 | -23.17 | -29.32 | -27.70 | -33.19 | -- | -- | -47.37 | -138.22 | -- | -- | 0.00 | -- | 642.47 | -12.81 | 61.16 | -- | -68.01 | -- |
| Palisade Bio Inc | 0.00 | -11.23m | 269.70m | 8.00 | -- | 5.14 | -- | -- | -2.98 | -2.98 | 0.00 | 0.3522 | 0.00 | -- | -- | 0.00 | -137.67 | -130.84 | -221.20 | -165.85 | -- | -- | -- | -31,830.91 | -- | -1,041.55 | 0.0616 | -- | -100.00 | -- | -17.38 | -- | -- | -- |
Data as of Mar 02 2026. Currency figures normalised to Shattuck Labs Inc's reporting currency: US Dollar USD
52.02%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| T. Rowe Price Investment Management, Inc.as of 31 Jan 2026 | 7.37m | 11.65% |
| Adage Capital Management LPas of 31 Dec 2025 | 6.31m | 9.97% |
| Redmile Group LLCas of 31 Dec 2025 | 5.54m | 8.75% |
| NEXTBio Capital Management LPas of 31 Dec 2025 | 3.15m | 4.98% |
| Prosight Management LPas of 31 Dec 2025 | 2.38m | 3.76% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 2.03m | 3.20% |
| T. Rowe Price Associates, Inc. (IM)as of 31 Dec 2025 | 1.93m | 3.04% |
| The Clark Estates, Inc.as of 31 Dec 2025 | 1.48m | 2.33% |
| 683 Capital Management LLCas of 31 Dec 2025 | 1.39m | 2.20% |
| Pinnacle Associates Ltd.as of 31 Dec 2025 | 1.35m | 2.13% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
